Advertisement For O'Reilly GlassAdvertisement For Smiths Of Drogheda
Monday, 6th January 2025

Merck Sharp & Dohme to acquire WuXi Vaccines site in Dundalk for €500m

Front Page

The WuXi/MSD building in Dundalk.

As part of its long-term plans in Ireland, the giant US biopharmaceutical company Merck Sharp & Dohme has agreed to acquire the WuXi Vaccines manufacturing facility in Dundalk for over €500 million.

The acquisition comes on the back of the company’s recent announcement of a €1 billion investment across its sites in Carlow and Dunboyne, Co Meath, just last year.

Merck Sharp & Dohme (MSD) and WuXi will now begin an official handover process which aims to be completed in the first half of 2025.  

MSD Ireland is looking ahead to significant growth across its network, and, including this acquisition, is planning to add approximately 1,000 jobs over coming years across its eight locations in counties Carlow, Cork, Dublin, Louth, Meath and Tipperary.  

Advertisement For Drogheda Credit Union Love to Lend

The newly acquired Dundalk site is a 15,520-square-meter, three-story vaccine manufacturing facility featuring drug substance manufacturing, drug product manufacturing, and quality control labs for the supply of vaccine products for the global market, currently employing approximately 200 professionals on site.  

This new acquisition by MSD is a testament to a successful collaboration and long-standing partnership between both companies over recent years, which saw MSD and WuXi collaborating in Dundalk since 2019.

“Today’s announcement is highly welcome news and is a tremendous vote of confidence in the people of Dundalk and Co. Louth” An Taoiseach Simon Harris, TD, said. “MSD is a long-standing partner to Ireland and has shown an unwavering commitment both to the country and to its drive to innovate.

“The acquisition of the Dundalk facility, along with the company’s plans to add 150 additional jobs to it, as part of an overall increase of 1,000 positions across its Irish operations in the coming years will play an important role in its development and delivery of innovative products that will improve the lives of millions of people around the world.”

Minister for Enterprise, Trade and Employment, Peter Burke, TD said: “Government and the IDA have prioritised the life-sciences sector over many years and this latest development is a testament to the strength of the sector in Ireland. While the IDA’s mandate from Government is to attract and retain global blue-chip manufacturing companies to Ireland, I am acutely conscious of the potential that investments such as this by MSD in Co. Louth have to also support strong spinoff opportunities for Ireland. I look forward to working with MSD and the IDA on securing further such signal investments for Ireland.”

Louth TD Erin McGreehan said the news is a vote of confidence in Louth and will bring jobs and investment to the Dundalk region.

"This announcement is hugely welcome and will provide a real boost to the economy in Dundalk and indeed across county Louth” she said.

"I look forward to working with MSD Ireland on their expansion in Louth, where their newly acquired Dundalk site focuses on drug substance manufacturing, drug product manufacturing and quality control labs for the supply of vaccine products for the global market."

Sanat Chattopadhyay, Executive Vice President and President of MSD’s Manufacturing Division, said: “MSD’s manufacturing footprint in Ireland is unparalleled, and I am proud to oversee its continuous expansion, always looking to advance the future of health through innovation and acceleration in the service of people and patients around the world. The acquisition of this WuXi site in Dundalk will give us the opportunity to do just that: deliver for people and patients faster, looking at the health challenges of today and tomorrow.”

MSD Ireland is one of the country’s leading healthcare companies, having first established in Ireland in 1976. At present, the company has a dynamic and diverse team of over 3,000 employees currently working across seven locations in counties Carlow, Cork, Dublin, Meath and Tipperary. Working across all stages of pharmaceutical development, the company’s Irish network is focused on leveraging innovation to respond to the health threats of today and tomorrow, working at the forefront of science and technology to advance manufacturing excellence and future focused R&D.

Advertisement For O'Reilly Glass
Advertisement For Smiths Of Drogheda